{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:52:08Z","timestamp":1794635528904,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["S202412121145"],"award-info":[{"award-number":["S202412121145"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202155"],"award-info":[{"award-number":["82202155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071949"],"award-info":[{"award-number":["82071949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515011882"],"award-info":[{"award-number":["2021A1515011882"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2023B03J1350"],"award-info":[{"award-number":["2023B03J1350"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M731552"],"award-info":[{"award-number":["2023M731552"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The efficacy of immunotherapy in triple-negative breast cancer (TNBC) is primarily challenged by its inherent low immunogenicity, which is further undermined by the immunosuppressive activity of tumor-associated polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). The hypoxic microenvironment renders PMN-MDSCs susceptible to ferroptosis and exacerbates immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to design a multifunctional nanoplatform comprising Cu\/Mn bimetallic metal-organic frameworks decorated with gold (Au) nanozymes (CMAP MOFs) that simultaneously enhances tumor immunogenicity and alleviates immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The characteristics of the nanosystem were evaluated using transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, and ultraviolet-visible spectrophotometry. In vitro experiments employed Western blotting, immunofluorescence, and flow cytometry to investigate the mechanisms of enhanced immunogenicity and alleviated immunosuppression in 4T1 cells. In vivo experiments evaluated the therapeutic efficacy of the nanosystem in BALB\/c mice bearing implanted 4T1 tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Within tumor cells, the CMAP MOFs undergo GSH-responsive disintegration. The released Cu\/Mn ions catalyze Fenton-like reaction to induce tumor cell ferroptosis and mitochondrial DNA damage, activating cGAS-STING pathway, and facilitating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells recruitment. Simultaneously, released Au nanozymes catalyze H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sub>2<\/jats:sub>\n                      conversion to O\n                      <jats:sub>2<\/jats:sub>\n                      , alleviating hypoxia and preventing PMN-MDSCs ferroptosis and associated immunosuppression. While the immunogenicity-enhancing CMP MOFs group increased CD8\u207a T cell infiltration from 21% to 28.3% with 74.1% tumor growth inhibition, the combined immunogenicity enhancement and immunosuppression relief CMAP MOFs group further boosted CD8\u207a T cell infiltration to 32.4% with superior tumor growth inhibition of 81.3%, with IFN-\u03b3 and GZMB expression elevated by 2.2-fold and 2.0-fold (CMP MOFs) and 3.4-fold and 3.0-fold (CMAP MOFs) compared to control. This strategy offers a promising approach for enhancing immunotherapy in TNBC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-026-04482-3","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:15:23Z","timestamp":1777133723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gold nanozyme-decorated Cu\/Mn MOFs simultaneously enhances immunogenicity and alleviates immunosuppression in triple-negative breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Haibo","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zede","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxiu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"4482_CR1","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan L, Strasser-Weippl K, Li J, et al. Breast cancer in China. LANCET ONCOL. 2014;15:e279\u201389.","journal-title":"LANCET ONCOL"},{"key":"4482_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA-J AM MED ASSOC. 2019;321:288\u2013300.","journal-title":"JAMA-J AM MED ASSOC"},{"key":"4482_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. ANNU REV PATHOL-MECH. 2022;17:181\u2013204.","journal-title":"ANNU REV PATHOL-MECH"},{"key":"4482_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. NAT REV CLIN ONCOL. 2019;16:151\u201367.","journal-title":"NAT REV CLIN ONCOL"},{"key":"4482_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, et al. Advances in immunotherapy for triple-negative breast cancer. MOL CANCER. 2023;22:145.","journal-title":"MOL CANCER"},{"key":"4482_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"4482_CR7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. NEW ENGL J MED. 2020;382:810\u201321.","journal-title":"NEW ENGL J MED"},{"key":"4482_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","volume":"35","author":"L Pusztai","year":"2024","unstructured":"Pusztai L, Denkert C, O\u2019Shaughnessy J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. ANN ONCOL. 2024;35:429\u201336.","journal-title":"ANN ONCOL"},{"key":"4482_CR9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","volume":"41","author":"G Escobar","year":"2023","unstructured":"Escobar G, Tooley K, Oliveras JP, et al. Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell. 2023;41:1662\u201379.","journal-title":"Cancer Cell"},{"key":"4482_CR10","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA NETW OPEN. 2019;2:e192535.","journal-title":"JAMA NETW OPEN"},{"key":"4482_CR11","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. NAT CANCER. 2022;3:1452\u201363.","journal-title":"NAT CANCER"},{"key":"4482_CR12","doi-asserted-by":"publisher","first-page":"109304","DOI":"10.1016\/j.intimp.2022.109304","volume":"113","author":"R Huang","year":"2022","unstructured":"Huang R, Ning Q, Zhao J, et al. Targeting STING for cancer immunotherapy: From mechanisms to translation. INT IMMUNOPHARMACOL. 2022;113:109304.","journal-title":"INT IMMUNOPHARMACOL"},{"key":"4482_CR13","doi-asserted-by":"publisher","first-page":"eadf837","DOI":"10.1126\/sciadv.adf0837","volume":"9","author":"G Su","year":"2023","unstructured":"Su G, Xiao Y, You C, et al. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets. SCI ADV. 2023;9:eadf837.","journal-title":"SCI ADV"},{"key":"4482_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding J, et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. CELL METAB. 2023;35:84\u2013100.","journal-title":"CELL METAB"},{"key":"4482_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830\u201349.","journal-title":"Cancer Cell"},{"key":"4482_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. NAT REV MOL CELL BIO. 2021;22:266\u201382.","journal-title":"NAT REV MOL CELL BIO"},{"key":"4482_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. NAT REV CLIN ONCOL. 2021;18:280\u201396.","journal-title":"NAT REV CLIN ONCOL"},{"key":"4482_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhou X, Xie F, et al. Ferroptosis in cancer and cancer immunotherapy. CANCER COMMUN. 2022;42:88\u2013116.","journal-title":"CANCER COMMUN"},{"key":"4482_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J EXP MED. 2018;215:1287\u201399.","journal-title":"J EXP MED"},{"key":"4482_CR20","doi-asserted-by":"crossref","unstructured":"Hu M, Zhou M, Bao X et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation. J CLIN INVEST 2021;131:e139333.","DOI":"10.1172\/JCI139333"},{"key":"4482_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. CANCER DISCOV. 2020;10:26\u201339.","journal-title":"CANCER DISCOV"},{"key":"4482_CR22","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.celrep.2020.108053","volume":"32","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Ma Z, Wang B, Guan Y, Su X, Jiang Z. Mn(2+) Directly Activates cGAS and Structural Analysis Suggests Mn(2+) Induces a Noncanonical Catalytic Synthesis of 2\u20193\u2019-cGAMP. CELL REP. 2020;32:108053.","journal-title":"CELL REP"},{"key":"4482_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, Chen M, Zhang R, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. CELL RES. 2020;30:966\u201379.","journal-title":"CELL RES"},{"key":"4482_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40820-025-01828-8","volume":"17","author":"M Xu","year":"2025","unstructured":"Xu M, Liu J, Feng L, et al. Designing a Sulfur Vacancy Redox Disruptor for Photothermoelectric and Cascade-Catalytic-Driven Cuproptosis-Ferroptosis-Apoptosis Therapy. NANO-MICRO LETT. 2025;17:321.","journal-title":"NANO-MICRO LETT"},{"key":"4482_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12951-024-02502-8","volume":"22","author":"H Hu","year":"2024","unstructured":"Hu H, Zheng S, He C, et al. Radiotherapy-sensitized cancer immunotherapy via cGAS-STING immune pathway by activatable nanocascade reaction. J NANOBIOTECHNOL. 2024;22:234.","journal-title":"J NANOBIOTECHNOL"},{"key":"4482_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. NAT IMMUNOL. 2018;19:108\u201319.","journal-title":"NAT IMMUNOL"},{"key":"4482_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cac2.12613","volume":"45","author":"J Yao","year":"2025","unstructured":"Yao J, Ji L, Wang G, Ding J. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms. CANCER COMMUN. 2025;45:15\u201342.","journal-title":"CANCER COMMUN"},{"key":"4482_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. TRENDS IMMUNOL. 2016;37:208\u201320.","journal-title":"TRENDS IMMUNOL"},{"key":"4482_CR29","doi-asserted-by":"crossref","unstructured":"Veglia F, Hashimoto A, Dweep H et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J EXP MED 2021;218:e20201803.","DOI":"10.1084\/jem.20201803"},{"key":"4482_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-022-05443-0","volume":"612","author":"R Kim","year":"2022","unstructured":"Kim R, Hashimoto A, Markosyan N, et al. Ferroptosis of tumor neutrophils causes immune suppression in cancer. Nature. 2022;612:338\u201346.","journal-title":"Nature"},{"key":"4482_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1039\/C9BM01742A","volume":"8","author":"Q Dan","year":"2020","unstructured":"Dan Q, Hu D, Ge Y, et al. Ultrasmall theranostic nanozymes to modulate tumor hypoxia for augmenting photodynamic therapy and radiotherapy. BIOMATER SCI-UK. 2020;8:973\u201387.","journal-title":"BIOMATER SCI-UK"},{"key":"4482_CR32","doi-asserted-by":"crossref","unstructured":"Liu C, Wu T, Liu C et al. Self-Supplying O(2) through the Catalase-Like Activity of Gold Nanoclusters for Photodynamic Therapy against Hypoxic Cancer Cells. SMALL 2017;13(26):1700278.","DOI":"10.1002\/smll.201700278"},{"key":"4482_CR33","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.apsb.2021.01.016","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Zhang L, Peng C, et al. Tumor microenvironments self-activated nanoscale metal-organic frameworks for ferroptosis based cancer chemodynamic\/photothermal\/chemo therapy. ACTA PHARM SIN B. 2021;11:3231\u201343.","journal-title":"ACTA PHARM SIN B"},{"key":"4482_CR34","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41423-021-00669-w","volume":"18","author":"R Zhang","year":"2021","unstructured":"Zhang R, Wang C, Guan Y, et al. Manganese salts function as potent adjuvants. CELL MOL IMMUNOL. 2021;18:1222\u201334.","journal-title":"CELL MOL IMMUNOL"},{"key":"4482_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2024.11.035","volume":"377","author":"Y Xia","year":"2025","unstructured":"Xia Y, Shi B, Wang K, et al. A trinity STING-activating nanoparticle harnesses cancer cell STING machinery for enhanced immunotherapy. J CONTROL RELEASE. 2025;377:256\u201366.","journal-title":"J CONTROL RELEASE"},{"key":"4482_CR36","doi-asserted-by":"publisher","first-page":"24555","DOI":"10.1021\/jacs.5c05148","volume":"147","author":"Q Li","year":"2025","unstructured":"Li Q, Zhang X, Zhang C, et al. Biomineralized Engineered Bacterial Outer Membrane Vesicles as cGAS-STING Nanoagonists Synergize with Lactate Metabolism Modulation to Potentiate Immunotherapy. J AM CHEM SOC. 2025;147:24555\u201372.","journal-title":"J AM CHEM SOC"},{"key":"4482_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","volume":"44","author":"R Kim","year":"2023","unstructured":"Kim R, Taylor D, Vonderheide RH, Gabrilovich DI. Ferroptosis of immune cells in the tumor microenvironment. TRENDS PHARMACOL SCI. 2023;44:542\u201352.","journal-title":"TRENDS PHARMACOL SCI"},{"key":"4482_CR38","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","volume":"30","author":"H Feng","year":"2020","unstructured":"Feng H, Schorpp K, Jin J, et al. Transferrin Receptor Is a Specific Ferroptosis Marker. CELL REP. 2020;30:3411\u201323.","journal-title":"CELL REP"},{"key":"4482_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","volume":"21","author":"B Chu","year":"2019","unstructured":"Chu B, Kon N, Chen D, et al. ALOX12 is required for p53-mediated tumor suppression through a distinct ferroptosis pathway. NAT CELL BIOL. 2019;21:579\u201391.","journal-title":"NAT CELL BIOL"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04482-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04482-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:29:04Z","timestamp":1781648944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04482-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4482"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04482-3","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments involving animals were conducted according to the ethical policies and procedures approved by The Institutional Animal Care And Use Committee of Southern Medical University (Approval No. SMUL2023111). Extensive efforts have been made to minimize suffering of animals during experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"565"}}